Valuation: SANA AB

Market Cap 1.83B 190M 166M 154M 141M 267M 18.31B 271M 720M 8.94B 714M 698M 30.87B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.83B 190M 166M 154M 141M 267M 18.31B 271M 720M 8.94B 714M 698M 30.87B EV / Sales 2026 *
6.86x
EV / Sales 2027 * 4.72x
Free-Float
81.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.82%
1 week+2.71%
Current month+1.22%
1 month+6.59%
3 months-15.80%
6 months-43.65%
Current year-37.41%
1 week 12.85
Extreme 12.85
13.59
1 month 12.42
Extreme 12.42
13.83
Current year 12.25
Extreme 12.25
28.3
1 year 8.03
Extreme 8.03
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 28/02/2025
Chief Executive Officer 66 29/04/2022
Chief Tech/Sci/R&D Officer 68 31/12/2013
Director TitleAgeSince
Chairman 71 29/04/2022
Director/Board Member 68 31/12/2014
Director/Board Member 46 18/01/2018
Date Insider Type Main position Quantity % Market Cap.
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%+2.71%+49.61%+74.15% 192M
-3.42%+4.90%+61.15%+87.70% 57.82B
-0.05%-5.85%+54.36%+124.61% 53.71B
-2.14%-9.13%+2.74%+421.65% 23.8B
-0.47%-1.53%-18.61%-15.41% 23.26B
-3.92%-0.26%+33.78%-7.32% 20.7B
-0.29%-2.05%+34.41%-27.98% 17.81B
-4.55%-1.95%+192.65%+349.58% 16.9B
-4.65%-3.54%+29.60%+662.36% 16.36B
+0.23%-2.49%+24.26%+187.16% 13.96B
Average -1.99%+0.97%+46.40%+185.65% 24.45B
Weighted average by Cap. -2.02%-0.15%+46.98%+164.25%

Financials

2026 *2027 *
Net sales 267M 27.7M 24.21M 22.39M 20.54M 38.88M 2.67B 39.56M 105M 1.3B 104M 102M 4.5B 388M 40.23M 35.16M 32.52M 29.84M 56.47M 3.88B 57.46M 152M 1.89B 151M 148M 6.53B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
43
Date Price Change Volume
16/07/26 SEK 13.27 -0.82% 212,281
15/07/26 SEK 13.38 +2.61% 312,232
14/07/26 SEK 13.04 -3.34% 319,042
13/07/26 SEK 13.49 +3.77% 298,811
10/07/26 SEK 13.00 +0.62% 472,816

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock